Nasal Decolonization

Nasal decolonization is a healthcare infection-prevention approach designed to reduce carriage of potentially harmful microorganisms in the nose, particularly Staphylococcus aureus, before or during periods of elevated clinical risk. It is used within broader prevention protocols that may include screening, antiseptic bathing, environmental hygiene, antimicrobial stewardship, and surveillance. Adoption is shaped by evidence quality, patient selection, protocol adherence, product availability, resistance considerations, and institutional infection-prevention priorities.

The field is shifting from isolated product use toward protocol-based prevention. Hospitals increasingly connect nasal screening or presumptive treatment with surgical pathways, intensive care, dialysis, transplantation, and other settings where healthcare-associated infection risk is closely monitored. Operational priorities include reducing staff burden, supporting rapid administration, standardizing documentation, and aligning interventions with local microbiology and antimicrobial-stewardship policies. Evidence remains context-dependent, so institutions must distinguish between universal and targeted approaches rather than assuming one protocol suits every population.

Artificial intelligence can strengthen nasal-decolonization programs by helping analyze microbiology results, identify patients who may benefit from targeted intervention, detect deviations from protocol, and connect decolonization activity with outcome surveillance. Predictive tools may also support risk stratification across surgical, critical-care, and other high-risk pathways. These applications require representative data, transparent validation, privacy safeguards, and clinical oversight. AI should support-not replace-laboratory confirmation, infection-prevention expertise, antimicrobial-stewardship review, and patient-specific decision-making.

North America generally emphasizes standardized hospital protocols, quality measurement, and integration with perioperative and intensive-care programs. Europe places strong weight on antimicrobial stewardship, national guidance, and variation among health systems. Asia-Pacific combines advanced hospital programs with substantial differences in laboratory capacity, access, and infection-control infrastructure. Latin America is influenced by uneven healthcare resources and the need for practical, scalable protocols. The Middle East shows growing interest in structured hospital infection prevention alongside variable implementation capacity. Africa’s priorities include strengthening surveillance, laboratory services, supply reliability, and feasible interventions that can operate across diverse care settings.

ASEAN members face wide variation in hospital capacity, surveillance maturity, and access to diagnostic services, making adaptable protocols important. BRICS countries span large and diverse healthcare systems, where local resistance patterns and procurement conditions materially affect implementation. The European Union benefits from cross-border public-health coordination but retains national differences in guidance and practice. G7 systems typically have stronger infection-prevention infrastructure and data capabilities, while still confronting workforce and compliance pressures. GCC health systems can leverage concentrated hospital networks and centralized programs, with attention to imported-care pathways and workforce mobility. NATO members may benefit from interoperable preparedness standards, particularly for high-consequence infection-control scenarios.

Australia and Canada can build on established infection-prevention systems while addressing geographic dispersion and workforce consistency. Brazil, Mexico, India, and South Africa require approaches that accommodate substantial variation among public, private, urban, and rural facilities. China, Japan, and South Korea have strong hospital and laboratory capabilities but differ in governance, procurement, and clinical workflow design. France, Germany, Italy, Spain, and the United Kingdom operate within mature health systems where stewardship, national guidance, and auditability are central considerations. Russia’s implementation environment is shaped by institutional variation, surveillance needs, and supply continuity. Across the United States, program design commonly depends on hospital quality priorities, payer requirements, local epidemiology, and the balance between screening-based and broader preventive protocols.

Leaders should begin with a clearly defined clinical objective, target population, and outcome measure. They should compare universal, targeted, and screening-led approaches against local microbiology, patient flow, staffing, and procurement realities. Implementation plans should include staff training, patient communication, administration tracking, adverse-event monitoring, resistance surveillance, and periodic protocol review. Decision-makers should favor evidence-supported products and procedures, avoid unnecessary antimicrobial exposure, and require transparent data on adherence and outcomes. Partnerships among infection-prevention teams, laboratories, surgeons, nurses, pharmacists, procurement leaders, and information-technology specialists can improve sustained performance.

This executive summary uses a structured review framework for nasal decolonization, emphasizing peer-reviewed clinical evidence, public-health and infection-prevention guidance, antimicrobial-stewardship principles, microbiology findings, and documented implementation practices. Interpretation considers intervention type, patient population, care setting, comparator, adherence, infection outcome, resistance implications, and follow-up duration. Regional, group, and country observations are framed as healthcare-system considerations rather than quantified rankings. Because recommendations can vary by pathogen, setting, baseline risk, and local resistance patterns, institutions should validate conclusions against current national guidance and facility-level data.

Nasal decolonization is most effective when treated as one component of a coordinated infection-prevention pathway rather than a standalone intervention. Sustainable programs connect appropriate patient selection with reliable administration, laboratory and outcome surveillance, stewardship oversight, and continuous improvement. Regional and country differences make local validation essential, while emerging analytics and AI may improve targeting and compliance when governed responsibly. Leaders should prioritize clinically relevant outcomes, operational feasibility, patient safety, and resistance prevention as they develop or refine their protocols.